Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer
Studies Shed Light On Racial Disparities Between Blacks, Whites With Breast Cancer
Shorter, Simpler Consent Form Proposed For Phase I Trials
How Much Is Life Worth? The $440 Billion Question
Sunitinib Prolongs Survival In Poor Prognosis, Study Finds
Breast MRI Recipients More Likely To Choose Mastectomy
Opioid Pain Reliever Approved With Risk Reduction Plan
NCI Cooperative Group Clinical Trials Approved
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program









